Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

Abstract

AR + /FOXA1 + expression defines a luminal-like TNBC subgroup affected with a worse outcome compared to other TNBC and a higher risk of late recurrences. This subgroup appears enriched in PIK3CA mutations, suggesting a role for PI3K inhibitors in this subgroup.

The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases

“…In recent years, the relationship between the expression of FOXA1 and prognosis has been investigated in various cancers, including breast and prostate cancer . However, the influence of FOXA1 expression on prognosis differs according to the primary site.…”

“…In recent years, the relationship between the expression of FOXA1 and prognosis has been investigated in various cancers, including breast and prostate cancer. [18][19][20][21][22][23][24][25][26][27][29][30][31][32][34][35][36][37] However, the influence of FOXA1 expression on prognosis differs according to the primary site. In SDC, we demonstrated that a high FOXA1 expression level was a good prognostic marker.…”

“…Androgen receptor requires its co‐regulatory protein forkhead box protein A1 (FOXA1) to form a productive transcription complex on chromatin to mediate the cell‐ and tissue‐specific regulation of the target gene expression, and to bring about the diverse biological actions of androgens . FOXA1 is known frequently as a ‘pioneer factor’, which binds highly compacted chromatin and renders bound genomic regions more accessible to other transcription factors, and which is expressed in many organs, including the prostate and mammary gland …”

“…13 FOXA1 is known frequently as a 'pioneer factor', which binds highly compacted chromatin and renders bound genomic regions more accessible to other transcription factors, [14][15][16][17] and which is expressed in many organs, including the prostate and mammary gland. [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] Only one previous report on a small study population has analysed the FOXA1 expression, as well as FOXA1 gene mutations in SDCs. 28 However, the clinicopathological significance remains unknown.…”

Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer

“…J. Shou Наличие экспрессии РА и FOXA1 при ТНРМЖ определяет неблагоприятное течение заболевания, характеризующееся снижением БРВ и ОВ [92].…”